Five-Year Outcomes and Cardiac Remodeling Following Left Atrial Appendage Occlusion

References

• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.27567408
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-024315724
   PubMed Web of Science ®Google Scholar
• Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol. 1995;25(2):452–459. doi:10.1016/0735-1097(94)00396-87829800
   PubMed Web of Science ®Google Scholar
• Turagam M, Velagapudi P, Kar S, et al. Cardiovascular Therapies Targeting Left Atrial Appendage. J Am Coll Cardiol. 2018;72(4):448–463. doi:10.1016/j.jacc.2018.05.04829954658
   PubMed Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–542. doi:10.1016/S0140-6736(09)61343-X19683639
   PubMed Web of Science ®Google Scholar
• Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12. doi:10.1016/j.jacc.2014.04.02924998121
   PubMed Web of Science ®Google Scholar
• Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122–3135. doi:10.1016/j.jacc.2020.04.06732586585
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151. doi:10.1161/CIR.000000000000066530686041
   PubMed Web of Science ®Google Scholar
• Turagam M, Osmancik P, Neuzil P, Dukkipati S, Reddy V. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol. 2020;76(23):2795–2797. doi:10.1016/j.jacc.2020.08.08933272374
   PubMed Web of Science ®Google Scholar
• Jie Q, Wang D, Liu B, et al. Does left atrial appendage (LAA) occlusion device alter the echocardiography and electrocardiogram parameters in patients with atrial fibrillation? Int J Cardiol. 2016;215:494–501. doi:10.1016/j.ijcard.2016.03.20427131771
   PubMed Web of Science ®Google Scholar
• Turagam M, Vuddanda V, Verberkmoes N, et al. Epicardial left atrial appendage exclusion reduces blood pressure in patients with atrial fibrillation and hypertension. J Am Coll Cardiol. 2018;72(12):1346–1353. doi:10.1016/j.jacc.2018.06.06630213326
   PubMed Web of Science ®Google Scholar
• Lakkireddy D, Turagam M, Afzal M, et al. Left atrial appendage closure and systemic homeostasis: the LAA HOMEOSTASIS Study. J Am Coll Cardiol. 2018;71(2):135–144. doi:10.1016/j.jacc.2017.10.09229325636
   PubMed Web of Science ®Google Scholar
• Ogata T, Matsuo R, Kiyuna F, et al. Left atrial size and long-term risk of recurrent stroke after acute ischemic stroke in patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2017;6(8):e006402. doi:10.1161/JAHA.117.00640228862939
   PubMed Web of Science ®Google Scholar
• Njoku A, Kannabhiran M, Arora R, et al. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis. Europace. 2018;20(1):33–42. doi:10.1093/europace/eux01328444307
   PubMed Web of Science ®Google Scholar
• Li S-J, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the swedish heart failure registry. Circ Heart Fail. 2015;8(5):871–879. doi:10.1161/CIRCHEARTFAILURE.115.00228526243796
   PubMed Web of Science ®Google Scholar
• Riad FS, Razak E, Saba S, Shalaby A, Nemec J. Recent heart rate history affects QT interval duration in atrial fibrillation. PLoS One. 2017;12(3):e0172962–e0172962. doi:10.1371/journal.pone.017296228273109
   PubMed Web of Science ®Google Scholar
• Huang HD, Waks JW, Steinhaus DA, Zimetbaum P. Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation. Heart Rhythm. 2016;13(7):1410–1417. doi:10.1016/j.hrthm.2016.02.01626921760
   PubMed Web of Science ®Google Scholar
• Wen S-N, Liu N, Li S-N, et al. QTc interval prolongation predicts arrhythmia recurrence after catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Circ J. 2015;79(5):1024–1030. doi:10.1253/circj.CJ-14-129025739859
   PubMed Web of Science ®Google Scholar
• Andrade JG, Roy D, Wyse DG, et al. Heart rate and adverse outcomes in patients with atrial fibrillation: a combined AFFIRM and AF-CHF substudy. Heart Rhythm. 2016;13(1):54–61. doi:10.1016/j.hrthm.2015.08.02826299677
   PubMed Web of Science ®Google Scholar
• Reusser A, Blum S, Aeschbacher S, et al. QTc interval, cardiovascular events and mortality in patients with atrial fibrillation. Int J Cardiol. 2018;252:101–105. doi:10.1016/j.ijcard.2017.11.07829203211
   PubMed Web of Science ®Google Scholar
• Schmidt B, Betts TR, Sievert H, et al. Incidence of pericardial effusion after left atrial appendage closure: the impact of underlying heart rhythm-Data from the EWOLUTION study. J Cardiovasc Electrophysiol. 2018;29(7):973–978. doi:10.1111/jce.1362629722469
   PubMed Web of Science ®Google Scholar
• Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation. 2011;123(4):417–424. doi:10.1161/CIRCULATIONAHA.110.97644921242484
   PubMed Web of Science ®Google Scholar
• Jazayeri M, Vuddanda V, Turagam M, et al. Safety profiles of percutaneous left atrial appendage closure devices: an analysis of the food and drug administration manufacturer and user facility device experience (MAUDE) database from 2009 to 2016. J Cardiovasc Electrophysiol. 2018;29(1):5–13. doi:10.1111/jce.1336228988455
   PubMed Web of Science ®Google Scholar
• Saw J, Lempereur M. Percutaneous left atrial appendage closure: procedural techniques and outcomes. JACC Cardiovasc Interv. 2014;7(11):1205–1220. doi:10.1016/j.jcin.2014.05.02625459035
   PubMed Web of Science ®Google Scholar
• Kataoka H. Pericardial and pleural effusions in decompensated chronic heart failure. Am Heart J. 2000;139(5):918–923. doi:10.1016/S0002-8703(00)90026-710783228
   PubMed Web of Science ®Google Scholar
• Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017;70(24):2964–2975. doi:10.1016/j.jacc.2017.10.02129103847
   PubMed Web of Science ®Google Scholar
• Giudici MC, Bhave PD. Left atrial appendage closure device in atrial fibrillation. Cardiol Clin. 2017;35(2):297–300. doi:10.1016/j.ccl.2016.12.01128411903
   PubMed Web of Science ®Google Scholar